Phio Pharmaceutical

$2.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (+2.85%) Today
-$0.07 (-2.42%) As of 11:39 AM UTC after-hours

Why Robinhood?

You can buy or sell PHIO and other stocks, options, and ETFs commission-free!

About PHIO

Phio Pharmaceuticals Corp. Common Stock, also called Phio Pharmaceutical, is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA. The listed name for PHIO is Phio Pharmaceuticals Corp. Common Stock.

CEO
Gerrit Dispersyn
Employees
11
Headquarters
Marlborough, Massachusetts
Founded
2011
Market Cap
18.31M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
438.81K
High Today
$2.90
Low Today
$2.73
Open Price
$2.85
Volume
671.61K
52 Week High
$10.85
52 Week Low
$1.60

Collections

PHIO Earnings

-$1.33
-$0.89
-$0.44
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 25, After Hours

You May Also Like

CVE
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure